Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Articles, Neurobiology of Disease

Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate

Izumi Maezawa and Lee-Way Jin
Journal of Neuroscience 14 April 2010, 30 (15) 5346-5356; DOI: https://doi.org/10.1523/JNEUROSCI.5966-09.2010
Izumi Maezawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee-Way Jin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Published eLetters

Guidelines

As a forum for professional feedback, submissions of letters are open to all. You do not need to be a subscriber. To avoid redundancy, we urge you to read other people's letters before submitting your own. Name, current appointment, place of work, and email address are required to send a letter, and will be published with your review. We also require that you declare any competing financial interests. Unprofessional submissions will not be considered or responded to.

Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

Vertical Tabs

Jump to comment:

  • Targeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disorders
    Ahmad Ghanizadeh
    Submitted on: 26 April 2010
  • Submitted on: (26 April 2010)
    Page navigation anchor for Targeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disorders
    Targeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disorders
    • Ahmad Ghanizadeh, Associate Professor of Psychiatry

    Maezawa et al. reported that a possible therapeutic target for Rett syndrome is microglia glutamate synthesis or release, confirm that NMDA glutamate receptor antagonist may improve autism spectrum disorders (ASD) (Niederhofer 2007), and suggest that glutaminase inhibitors or gap junction hemichannel blockers may be appropriate therapeutic targets.

    Another potential therapeutic target is peroxynitrite. Agonists of NMDA...

    Show More

    Maezawa et al. reported that a possible therapeutic target for Rett syndrome is microglia glutamate synthesis or release, confirm that NMDA glutamate receptor antagonist may improve autism spectrum disorders (ASD) (Niederhofer 2007), and suggest that glutaminase inhibitors or gap junction hemichannel blockers may be appropriate therapeutic targets.

    Another potential therapeutic target is peroxynitrite. Agonists of NMDA receptors increase concentration of calcium leads to nitric oxide (NO) synthesis. NO reacts with free radical superoxide and produces the powerful oxidant peroxynitrite. Nitric oxide and peroxynitrite may cause glutamate release and neuronal death (Brown and Neher), and peroxynitrite is toxic for mitochondrial activity and DNA (Spencer, Wong et al. 1996). The hyperglutaminergic condition in ASD, the role of glutamate in production of inflammation (which is elevated in ASD; Blaylock and Strunecka, 2009), and peroxynitrite, toxicity of peroxynitrite for DNA, and the prevention of neuronal loss by scavengers of peroxynitrite in co-cultured neurons (Mander and Brown 2005) all point to peroxynitrite as a novel potential treatment target for autism.

    Peroxynitrite decomposition catalysts block nitration of glutamate transporters, especially GLT1 and glutamine synthetase (Chen, Muscoli et al.). These two proteins have key roles in transmission of glutamate into the intracellular space. Inhibition of GLT1 and glutamine synthetase by peroxynitrite increases glutamate level and causes neurotoxicity. Therefore, therapeutic approaches intelligently targeting peroxynitrite in brain could be worthwhile to be further studied in preclinical experimental trials for management of ASD. Of course, it is a simplification of the association of peroxynitrite and glutamate with the proposed intervention here. Peroxynitrite has roles in other tissues that should be considered before jumping to this conclusion.

    References

    Blaylock, R. L. and A. Strunecka (2009). "Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders." Curr Med Chem 16(2): 157-70.

    Brown, G. C. and J. J. Neher (2010). "Inflammatory Neurodegeneration and Mechanisms of Microglial Killing of Neurons." Mol Neurobiol. Mar 2. [Epub ahead of print].

    Chen, Z., C. Muscoli, et al. (2010). "NMDA-receptor activation and nitroxidative regulation of the glutamatergic pathway during nociceptive processing." Pain 149(1):100-6.

    Maezawa, I. and L. W. Jin (2010) "Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate." J Neurosci 30(15): 5346- 56.

    Mander, P. and G. C. Brown (2005). "Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration." J Neuroinflammation 2: 20.

    Niederhofer, H. (2007). "Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism." J Clin Psychopharmacol 27(3): 317-8.

    Spencer, J. P., J. Wong, et al. (1996). "Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosydnonimine." Chem Res Toxicol 9(7): 1152-8.

    Show Less
    Competing Interests: None declared.
Back to top

In this issue

The Journal of Neuroscience: 30 (15)
Journal of Neuroscience
Vol. 30, Issue 15
14 Apr 2010
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate
Izumi Maezawa, Lee-Way Jin
Journal of Neuroscience 14 April 2010, 30 (15) 5346-5356; DOI: 10.1523/JNEUROSCI.5966-09.2010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Rett Syndrome Microglia Damage Dendrites and Synapses by the Elevated Release of Glutamate
Izumi Maezawa, Lee-Way Jin
Journal of Neuroscience 14 April 2010, 30 (15) 5346-5356; DOI: 10.1523/JNEUROSCI.5966-09.2010
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Responses to this article

Respond to this article

Jump to comment:

  • Targeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disorders
    Ahmad Ghanizadeh
    Published on: 26 April 2010
  • Published on: (26 April 2010)
    Page navigation anchor for Targeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disorders
    Targeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disorders
    • Ahmad Ghanizadeh, Associate Professor of Psychiatry

    Maezawa et al. reported that a possible therapeutic target for Rett syndrome is microglia glutamate synthesis or release, confirm that NMDA glutamate receptor antagonist may improve autism spectrum disorders (ASD) (Niederhofer 2007), and suggest that glutaminase inhibitors or gap junction hemichannel blockers may be appropriate therapeutic targets.

    Another potential therapeutic target is peroxynitrite. Agonists of NMDA...

    Show More

    Maezawa et al. reported that a possible therapeutic target for Rett syndrome is microglia glutamate synthesis or release, confirm that NMDA glutamate receptor antagonist may improve autism spectrum disorders (ASD) (Niederhofer 2007), and suggest that glutaminase inhibitors or gap junction hemichannel blockers may be appropriate therapeutic targets.

    Another potential therapeutic target is peroxynitrite. Agonists of NMDA receptors increase concentration of calcium leads to nitric oxide (NO) synthesis. NO reacts with free radical superoxide and produces the powerful oxidant peroxynitrite. Nitric oxide and peroxynitrite may cause glutamate release and neuronal death (Brown and Neher), and peroxynitrite is toxic for mitochondrial activity and DNA (Spencer, Wong et al. 1996). The hyperglutaminergic condition in ASD, the role of glutamate in production of inflammation (which is elevated in ASD; Blaylock and Strunecka, 2009), and peroxynitrite, toxicity of peroxynitrite for DNA, and the prevention of neuronal loss by scavengers of peroxynitrite in co-cultured neurons (Mander and Brown 2005) all point to peroxynitrite as a novel potential treatment target for autism.

    Peroxynitrite decomposition catalysts block nitration of glutamate transporters, especially GLT1 and glutamine synthetase (Chen, Muscoli et al.). These two proteins have key roles in transmission of glutamate into the intracellular space. Inhibition of GLT1 and glutamine synthetase by peroxynitrite increases glutamate level and causes neurotoxicity. Therefore, therapeutic approaches intelligently targeting peroxynitrite in brain could be worthwhile to be further studied in preclinical experimental trials for management of ASD. Of course, it is a simplification of the association of peroxynitrite and glutamate with the proposed intervention here. Peroxynitrite has roles in other tissues that should be considered before jumping to this conclusion.

    References

    Blaylock, R. L. and A. Strunecka (2009). "Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders." Curr Med Chem 16(2): 157-70.

    Brown, G. C. and J. J. Neher (2010). "Inflammatory Neurodegeneration and Mechanisms of Microglial Killing of Neurons." Mol Neurobiol. Mar 2. [Epub ahead of print].

    Chen, Z., C. Muscoli, et al. (2010). "NMDA-receptor activation and nitroxidative regulation of the glutamatergic pathway during nociceptive processing." Pain 149(1):100-6.

    Maezawa, I. and L. W. Jin (2010) "Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate." J Neurosci 30(15): 5346- 56.

    Mander, P. and G. C. Brown (2005). "Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration." J Neuroinflammation 2: 20.

    Niederhofer, H. (2007). "Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism." J Clin Psychopharmacol 27(3): 317-8.

    Spencer, J. P., J. Wong, et al. (1996). "Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosydnonimine." Chem Res Toxicol 9(7): 1152-8.

    Show Less
    Competing Interests: None declared.

Related Articles

Cited By...

More in this TOC Section

Articles

  • Choice Behavior Guided by Learned, But Not Innate, Taste Aversion Recruits the Orbitofrontal Cortex
  • Maturation of Spontaneous Firing Properties after Hearing Onset in Rat Auditory Nerve Fibers: Spontaneous Rates, Refractoriness, and Interfiber Correlations
  • Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration
Show more Articles

Neurobiology of Disease

  • Macrophage Migration Inhibitory Factor (MIF) Makes Complex Contributions to Pain-Related Hyperactivity of Nociceptors after Spinal Cord Injury
  • Blocking Mitochondrial Zn2+ Accumulation after Ischemia Reduces Mitochondrial Dysfunction and Neuronal Injury
  • Three Dimensions of Association Link Migraine Symptoms and Functional Connectivity
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2022 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.